Infinity Pharmaceuticals Inc (INFI.OQ)
INFI.OQ on NASDAQ Stock Exchange Global Select Market
1.91USD
20 Jul 2018
1.91USD
20 Jul 2018
Change (% chg)
$-0.07 (-3.54%)
$-0.07 (-3.54%)
Prev Close
$1.98
$1.98
Open
$1.99
$1.99
Day's High
$2.00
$2.00
Day's Low
$1.89
$1.89
Volume
41,169
41,169
Avg. Vol
95,146
95,146
52-wk High
$3.75
$3.75
52-wk Low
$0.93
$0.93
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Mar '18 | 0.00 | -0.182 |
| FY 2017 | Dec '17 | 0.00 | 1.324 |
| Sep '17 | 6.00 | -0.140 | |
| Jun '17 | 0.00 | -0.336 | |
| Mar '17 | 0.00 | -0.208 | |
| FY 2016 | Dec '16 | 0.00 | -0.458 |
| Sep '16 | 0.00 | -0.393 | |
| Jun '16 | 9.47 | 1.072 | |
| Mar '16 | 9.26 | -0.824 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-18 | 3 | 0.00 | 0.00 | 0.00 | 29.70 |
| Quarter Ending Dec-18 | 3 | 0.67 | 2.00 | 0.00 | 29.70 |
| Year Ending Dec-18 | 4 | 0.50 | 2.00 | 0.00 | 29.67 |
| Year Ending Dec-19 | 4 | 5.50 | 22.00 | 0.00 | 0.00 |
| Earnings (per share) | |||||
| Quarter Ending Sep-18 | 4 | -0.20 | -0.18 | -0.22 | -0.73 |
| Quarter Ending Dec-18 | 4 | -0.19 | -0.16 | -0.22 | -0.73 |
| Year Ending Dec-18 | 4 | -0.75 | -0.71 | -0.78 | -1.42 |
| Year Ending Dec-19 | 4 | -0.71 | -0.59 | -0.88 | -0.84 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 85.33 | 32.76 | |
| P/E High - Last 5 Yrs. | -- | 298.33 | 45.44 | |
| P/E Low - Last 5 Yrs. | -- | 91.43 | 24.26 | |
| Beta | 2.69 | 0.93 | 0.89 | |
| Price to Sales (TTM) | -- | 112.52 | 5.73 | |
| Price to Book (MRQ) | 1.36 | 15.54 | 5.47 | |
| Price to Tangible Book (MRQ) | 1.37 | 14.64 | 7.05 | |
| Price to Cash Flow (TTM) | -- | 72.59 | 23.29 | |
| % Owned Institutions | 71.60 | 14.53 | 2.21 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 0.35 | 1.51 | |
| Dividend Yield - 5 Year Avg | -- | 0.27 | 1.52 | |
| Dividend 5 Year Growth Rate | -- | 1.70 | 5.22 | |
| Payout Ratio(TTM) | -- | 16.35 | 43.77 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -100.00 | 408.02 | 8.01 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -100.00 | 79.88 | 5.64 | |
| Sales - 5 Yr. Growth Rate | -27.39 | 32.06 | 10.18 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -131.35 | 29.02 | 20.60 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -581.56 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 39.49 | 10.66 | |
| Capital Spending - 5 Yr. Growth Rate | -15.59 | 39.97 | 15.33 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 1.92 | 2.22 |
| Current Ratio (MRQ) | 6.29 | 5.50 | 3.03 |
| LT Debt to Equity (MRQ) | 35.31 | 34.92 | 12.51 |
| Total Debt to Equity (MRQ) | 36.09 | 36.72 | 16.84 |
| Interest Coverage (TTM) | -- | -101.16 | 32.64 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 39.68 | 54.37 | |
| Gross Margin - 5 Yr. Avg. | -- | 50.98 | 52.17 | |
| EBITD Margin (TTM) | -- | -- | -- | |
| EBITD - 5 Yr. Avg | -146.16 | -586.56 | 10.81 | |
| Operating Margin (TTM) | -- | -733.21 | 4.58 | |
| Operating Margin - 5 Yr. Avg. | -101.91 | -608.15 | 6.23 | |
| Pre-Tax Margin (TTM) | -- | -707.36 | 5.43 | |
| Pre-Tax Margin - 5 Yr. Avg. | -104.77 | -611.67 | 6.67 | |
| Net Profit Margin (TTM) | -- | -708.75 | 1.73 | |
| Net Profit Margin - 5 Yr. Avg. | -104.92 | -614.69 | 2.94 | |
| Effective Tax Rate (TTM) | -- | 23.23 | 23.11 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 18.56 | 23.98 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 0 | 23,025,841 | 860,394,083 | |
| Net Income/Employee (TTM) | -3,037,261 | 3,117,868 | 101,209,433 | |
| Receivable Turnover (TTM) | -- | 20.74 | 5.87 | |
| Inventory Turnover (TTM) | -- | 2.46 | 3.41 | |
| Asset Turnover (TTM) | 0.00 | 0.41 | 0.94 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -50.23 | 0.27 | 11.14 | |
| Return on Assets - 5 Yr. Avg. | -26.43 | 3.72 | 12.40 | |
| Return on Investment (TTM) | -62.67 | 2.22 | 14.61 | |
| Return on Investment - 5 Yr. Avg. | -30.82 | 2.89 | 16.14 | |
| Return on Equity (TTM) | -78.61 | 3.86 | 16.34 | |
| Return on Equity - 5 Yr. Avg. | -41.07 | 3.83 | 17.40 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -82.83 | -- | -27.39 |
| EPS (TTM) % | 76.80 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Infinity Pharmaceuticals Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | 31.40 | 26.87 | 90 | 53 |
| 13 Week | 5.30 | 0.17 | 61 | 66 |
| 26 Week | -34.30 | -39.29 | 18 | 79 |
| 52 Week | 3.25 | -12.49 | 54 | 52 |
| YTD | 17.78 | 3.43 | 58 | 61 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Infinity Pharmaceuticals Q1 Loss Per Share $0.18
- BRIEF-Infinity Pharmaceuticals Q1 Loss Per Share $0.18
- BRIEF-Infinity Pharmaceuticals Files Prospectus Relates To Resale Of Up To 1.1 Mln Shares Of Co's Common Stock - SEC Filing
- BRIEF-BVF Partners Reports 21.7 Pct Stake In Infinity Pharmaceuticals As Of April 10
- BRIEF-Infinity Pharma Qtrly Diluted Loss Per Common Share $0.14
Institutional Holders
| % Shares Owned: | 62.42% |
| # of Holders: | 82 |
| Total Shares Held: | 34,999,252 |
| 3 Mo. Net Change: | 5,481,790 |
| # New Positions: | 1 |
| # Closed Positions: | 2 |
| # Increased Positions: | 2 |
| # Reduced Positions: | 2 |
| # Net Buyers: | 0 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.